Fulgent Genetics Inc. (FLGT)
NASDAQ: FLGT
· Real-Time Price · USD
21.81
-0.21 (-0.95%)
At close: Sep 03, 2025, 3:59 PM
-0.95% (1D)
| Bid | 21.71 |
| Market Cap | 667.53M |
| Revenue (ttm) | 303.22M |
| Net Income (ttm) | -51.02M |
| EPS (ttm) | -1.66 |
| PE Ratio (ttm) | -13.14 |
| Forward PE | -33.8 |
| Analyst | Buy |
| Ask | 21.94 |
| Volume | 3,385 |
| Avg. Volume (20D) | 268,180 |
| Open | 21.90 |
| Previous Close | 22.02 |
| Day's Range | 21.66 - 21.92 |
| 52-Week Range | 14.57 - 23.56 |
| Beta | 0.83 |
About FLGT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol FLGT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for FLGT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Fulgent Genetics Inc. is scheduled to release its earnings on
Nov 7, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 weeks ago
+13.18%
Fulgent Genetics shares are trading higher after U...
Unlock content with
Pro Subscription
1 month ago
+7.86%
Fulgent Genetics shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 guidance above estimates.
1 month ago · fool.com
Fulgent (FLGT) Q2 Revenue Jumps 16%Fulgent (FLGT) Q2 Revenue Jumps 16%
1 month ago · businesswire.com
Fulgent Genetics Receives EU CE Mark for FulgentExome & FulgentPLMEL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeuti...
2 months ago · https://www.defenseworld.net
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 5,986 Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT – Free Report) by 13.4% during the fourth quarter, ac...
